Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CBIO

Crescent Biopharma, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CBIO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Crescent Biopharma, Inc. (NASDAQ: CBIO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 04:35 UTC.

What Crescent Biopharma, Inc. does

The company is a clinical-stage biotechnology firm incorporated in Delaware in 2003 and reorganized through a reverse merger with Crescent Biopharma, shifting its incorporation to the Cayman Islands. It focuses on developing cancer therapies through two main strategies: CR-001, a bispecific antibody targeting PD-1 and VEGF designed to work as an immuno-oncology backbone, and a portfolio of antibody drug conjugates, or ADCs.

Summarized from Crescent Biopharma, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-75.83%

Revenue, margins & earnings

FY2021: net loss $63M on revenue $1M$1MFY2021FY2022: net loss $47M on revenue $75,000$75,000FY2022FY2023: net loss $37M on revenue $10,000$10,000FY2023FY2025: net loss $154M on revenue $11M$11MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-18
  • 2026-09-18Chief Financial OfficerSale-568$10.2K
  • 2026-09-18See RemarksSale-240$4.3K
  • 2026-09-18Chief Executive OfficerSale-7,837$131.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Crescent Biopharma, Inc. do?

The company is a clinical-stage biotechnology firm incorporated in Delaware in 2003 and reorganized through a reverse merger with Crescent Biopharma, shifting its incorporation to the Cayman Islands.

When did CBIO last file with the SEC?

Crescent Biopharma, Inc.'s most recent SEC filing on record is a 10-Q/A filed 2026-06-22. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 04:35 UTC. This page is also available as JSON at /api/data?ticker=CBIO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CBIO and 5,000+ tickers.

Create a free account — keep CBIO
For your agent
GET /api/data?ticker=CBIO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt